home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490519.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
2KB
|
39 lines
Document 0519
DOCN M9490519
TI [Clinical applications of erythropoietin]
DT 9411
AU Robak T; II Kliniki Chorob Wewnetrznych AM w Lodzi.
SO Acta Haematol Pol. 1994;25(2 Suppl 1):112-23. Unique Identifier :
AIDSLINE MED/94346212
AB Erythropoietin (EPO) is a glycoprotein produced primarily by the kidney
in response to tissue hypoxia, and is the principal factor regulating
red blood cell production. It stimulates erythroid precursors in the
bone marrow to proliferate and mature into morphologically identifiable
red blood cells. This hormone acts by binding to specific high-affinity
receptor on erythroid precursors. Failure to produce adequate quantities
of EPO leads to severe anemia, a situation most often encountered in
patients with end stage renal disease. With the application of
recombinant DNA technology, the gene for this hormone has been
molecularly cloned, sequenced and expressed in a biologically active
form in mammalian cells. The recombinant EPO has been demonstrated to
correct anemia in patients with severe end stage renal disease and
alleviate their transfusion requirements. It has also been studied for
anemia associated with HIV infection/zidovudine therapy, in cancer,
rheumatoid arthritis, and prematurity. In addition it has been studied
as a facilitator of autologous blood predeposit in patients scheduled
for elective surgery and as a perisurgical adjuvant to hasten
hematologic recovery and possibly avoid the need for homologous
transfusion after elective surgery. When administered with the current
guidelines EPO appears to be safe drug with favorable risk/benefit
ratio.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS
Anemia/ETIOLOGY/*PREVENTION & CONTROL English Abstract
Erythropoietin/*THERAPEUTIC USE Human Kidney Failure,
Chronic/COMPLICATIONS Myelodysplastic Syndromes/THERAPY
Neoplasms/COMPLICATIONS Recombinant Proteins JOURNAL ARTICLE REVIEW
REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).